DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (1658)

Asthma | Access & Reimbursement | Detailed, Expanded Analysis (US)

Asthma | Access & Reimbursement | Detailed, Expanded Analysis (US)

Thank you!

Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.

Market Outlook
The dynamics within the LABA/ICS FDC, LAMA , and biological drug classes will continue to shape the asthma market. The dominance of branded LABA/ICS FDCs (, GSK’s Advair , AstraZeneca’s Symbicort ) will be called into question, as new generic/branded-generic agents continue to launch over the next several years. In addition, the market entrance of LABA/LAMA/ICS FDCs could create uptake challenges for Boehringer Ingelheim’s Spiriva —which, despite notable previous off-label use, was only recently approved for asthma. Finally, the launch of novel biologics will fuel increasing competition and pricing pressure in the severe, refractory segment of the asthma market. Overall, with the impending entry of multiple new branded and generic therapies, marketers of current—and emerging—asthma agents will be faced with increasing challenges to gain favorable formulary position and market uptake.
Questions Answered

Which key asthma therapies (, Advair, Symbicort, GSK’s Breo, Novartis’s Xolair, GSK’s Nucala, Teva’s Cinqair) receive favorable formulary placement, and what approaches do payers employ to manage utilization and costs?
How do reimbursement restrictions impact physicians’ prescribing of LABA/ICS FDCs, Spiriva, and biologics to their asthma patients?
How do payers expect current and emerging generic/branded-generic versions of market-leading LABA/ICS FDCs (, Teva’s AirDuo RespiClick/authorized generic, AB-rated generics of Advair and Symbicort) will impact access to branded therapies? How do physicians expect to prescribe these generics/branded-generic alternatives?
How do physicians anticipate using select emerging biologics (, AstraZeneca’s Fasenra [benralizumab], Sanofi/Regeneron’s Dupixent [dupilumab]) and LABA/LAMA/ICS FDCs (, GSK’s Trelegy [vilanterol/umeclidinium/fluticasone furoate]), and how do payers expect to cover these therapies on commercial health plans at various price points?

Product  Description
Access & Reimbursement: Provides in-depth insight regarding the impact of payer policy on physician prescribing behavior so you can build your market access strategy and optimize your brand positioning.

  • Pub Date: December 2017
  • Author(s): Elena Kozhemyakina, PhD

Request report

Related reports:
You may also be interested in: